AGTC - Applied Genetic jumps 6% on encouraging achromatopsia trial results

Applied Genetic Technologies (AGTC) jumps 6.2% premarket after reporting 12-month data from its ongoing achromatopsia ((ACHM)) Phase 1/2 clinical trials, including data from all adult patients and low-dose pediatric patients.ACHM B3 12-Month Results: 12-month data, which are available for 25 patients, consisting of 21 adult and 4 pediatric (<18 years of age) patients, show continued improvements on perimetry for higher dose and younger patients and include positive patient anecdotes.Improvements in retinal sensitivity were seen in the treated eye compared with the untreated eye in 4 of 11 patients from the high-dose and pediatric cohorts.Improvements in light discomfort as measured by OPA, were also observed in 6 of these 11 patients.Improvements in light discomfort also were observed in the untreated eye of these patients, which suggests possible cortical adaptation within the brain.In addition, the safety profile of the Company’s ophthalmic gene therapy platform remained favorable.Based on these data, AGTC intends to advance the

For further details see:

Applied Genetic jumps 6% on encouraging achromatopsia trial results